Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 7/20 | 0.58 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.58 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.58 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.58 |
| ▸ | PRCP | P42785 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15334650 | 1.00 | PNMT (0.58) | PNMTADRA2AADRA2BADRA2CPRCP | |
| SCHEMBL31159189 | 1.00 | PNMT (0.58) | PNMTADRA2AADRA2BADRA2CPRCP | |
| SCHEMBL1690519 | 1.00 | PNMT (0.58) | PNMTADRA2AADRA2BADRA2CPRCP | |
| SCHEMBL29590929 | 1.00 | PNMT (0.58) | PNMTADRA2AADRA2BADRA2CPRCP | |
| SCHEMBL1690518 | 1.00 | PNMT (0.58) | PNMTADRA2AADRA2BADRA2CPRCP | |
| Hydrochloric Acid SCHEMBL16412125 | 0.98 | PNMT (0.56) | PNMTADRA2AADRA2BADRA2CPRCP | |
| Hydrochloric Acid SCHEMBL17838213 | 0.98 | PNMT (0.56) | PNMTADRA2AADRA2BADRA2CPRCP | |
| Hydrochloric Acid SCHEMBL29590845 | 0.98 | PNMT (0.56) | PNMTADRA2AADRA2BADRA2CPRCP | |
| SCHEMBL5766795 | 0.80 | HTR2C (0.50) | PNMTADRA2AADRA2BADRA2CPRCP | |
| Hydrochloric Acid SCHEMBL11458153 | 0.78 | HTR2C (0.48) | PNMTADRA2AADRA2BADRA2CPRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109943861-B | Method for synthesizing alpha-phosphoramidate by electrochemical oxidation | 南京大学 | 2020-11-27 | — | — | CN | claimed |
| US-20090221562-A1 | NOVEL OPIOID ANTAGONISTS | ADOLOR CORPORATION (US) | 2009-09-03 | — | — | US | claimed |
| US-7538110-B2 | e.g. 1-(8-(3-hydroxyphenyl)-7,8-dimethyl-hexahydro-1H-pyrido[1,2- alpha ]pyrazin-2(6H)-yl)-2-phenylethanone; analgesics; gastrointestinal dysfunction, post-surgical recovery; side effect reduction | ADOLOR CORPORATION (US) | 2009-05-26 | — | — | US | claimed |
| EP-1940412-A2 | NOVEL OPIOID ANTAGONISTS | Adolor Corporation (US) | 2008-07-09 | — | — | EP | claimed |
| US-20070105863-A1 | e.g. 1-(8-(3-hydroxyphenyl)-7,8-dimethyl-hexahydro-1H-pyrido[1,2- alpha ]pyrazin-2(6H)-yl)-2-phenylethanone; analgesics; gastrointestinal dysfunction, post-surgical recovery; side effect reduction | MERCK SHARP & DOHME LLC | 2007-05-10 | — | — | US | claimed |
| WO-2007050802-A2 | NOVEL OPIOID ANTAGONISTS | ADOLOR CORPORATION (US) | 2007-05-03 | — | — | WO | claimed |
| EP-0230242-A2 | Substituted derivatives of 4-amino-3-hydroxy-butyric acid, process for their production, medicines containing them, and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-07-29 | — | — | EP | claimed |
| US-20250171420-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | MONTE ROSA THERAPEUTICS AG (CH) | 2025-05-29 | — | — | US | disclosed |
| US-20240368136-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-11-07 | — | — | US | disclosed |
| EP-3365334-B1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2024-07-17 | — | — | EP | disclosed |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-11939321-B2 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-03-26 | — | — | US | disclosed |
| US-5686458-A | Quinazoline deriviates for treating peptic ulcer | YUHAN CORPORATION (KR) | 1997-11-11 | — | — | US | disclosed |
| EP-0677049-A1 | QUINAZOLINE DERIVATIVES | YUHAN CORPORATION, LTD. (KR) | 1995-10-18 | — | — | EP | disclosed |
| WO-1994014795-A1 | QUINAZOLINE DERIVATIVES | YUHAN CORPORATION (KR) | 1994-07-07 | — | — | WO | disclosed |
| EP-0544748-A1 | SPIRO CYCLOALKYLBENZENE-1,1'-(1',2',3',4'-TETRAHYDROISOQUINOLINES)] HAVING NEUROPROTECTIVE PROPERTIES. | FISONS CORP (US) | 1993-06-09 | — | — | EP | disclosed |
| WO-1992003420-A1 | SPIRO[CYCLOALKYLBENZENE-1,1'-(1',2',3',4'-TETRAHYDROISOQUINOLINES)] HAVING NEUROPROTECTIVE PROPERTIES | FISONS CORPORATION (US) | 1992-03-05 | — | — | WO | disclosed |
| EP-0230242-A2 | Substituted derivatives of 4-amino-3-hydroxy-butyric acid, process for their production, medicines containing them, and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-07-29 | — | — | EP | disclosed |
| US-4228170-A | INHIBITOR OF PHENYLETHANOLAMINE N-METHYLTRANSFERASE | SMITHKLINE CORPORATION (US) | 1980-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11939321-B2 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | PNMT 1178/4885ADRA2A 2563/4885ADRA2B 2372/4885 |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | PNMT 3763/4885ADRA2A 4442/4885ADRA2B 4545/4885 |
| US-20090221562-A1 | NOVEL OPIOID ANTAGONISTS | OPRK1, OPRM1, OPRL1 | PNMT 223/4885ADRA2A 11/4885ADRA2B 15/4885 |
| US-20240368136-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | PNMT 1190/4885ADRA2A 2544/4885ADRA2B 2380/4885 |
| US-20250171420-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | PSMA1, CSNK1G1, CSNK1A1 | PNMT 1870/4885ADRA2A 4107/4885ADRA2B 4317/4885 |
| US-20070105863-A1 | e.g. 1-(8-(3-hydroxyphenyl)-7,8-dimethyl-hexahydro-1H-pyrido[1,2- alpha ]pyrazin-2(6H)-yl)-2-phenylethanone; analgesics; gastrointestinal dysfunction, post-surgical recovery; side effect reduction | OPRK1, OPRD1, OPRM1 | PNMT 62/4885ADRA2A 13/4885ADRA2B 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.